Furthermore, obese cancer patients could be at heightened risk of diabetes if treated with SphK/S1P inhibitors and this concept needs to be considered in future research in SphK/S1P inhibitor design and treatment. The gene discussed is MBTPS1; the disease is diabetes mellitus.